WO2003104811A3 - Utilisation diagnostique et therapeutique de la proteine regulatrice de reponse steroidogene aigue pour traiter des maladies neurodegeneratives - Google Patents

Utilisation diagnostique et therapeutique de la proteine regulatrice de reponse steroidogene aigue pour traiter des maladies neurodegeneratives Download PDF

Info

Publication number
WO2003104811A3
WO2003104811A3 PCT/EP2003/005910 EP0305910W WO03104811A3 WO 2003104811 A3 WO2003104811 A3 WO 2003104811A3 EP 0305910 W EP0305910 W EP 0305910W WO 03104811 A3 WO03104811 A3 WO 03104811A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
regulatory protein
neurodegenerative diseases
diagnostic
therapeutic use
Prior art date
Application number
PCT/EP2003/005910
Other languages
English (en)
Other versions
WO2003104811A2 (fr
Inventor
Thomas Hesterkamp
Der Kammer Heinz Von
Ralf Krappa
Johannes Pohlner
Original Assignee
Evotec Neurosciences Gmbh
Thomas Hesterkamp
Der Kammer Heinz Von
Ralf Krappa
Johannes Pohlner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh, Thomas Hesterkamp, Der Kammer Heinz Von, Ralf Krappa, Johannes Pohlner filed Critical Evotec Neurosciences Gmbh
Priority to JP2004511831A priority Critical patent/JP2005531305A/ja
Priority to AU2003240746A priority patent/AU2003240746A1/en
Priority to EP03730155A priority patent/EP1512013A2/fr
Priority to US10/517,439 priority patent/US20070118913A1/en
Publication of WO2003104811A2 publication Critical patent/WO2003104811A2/fr
Publication of WO2003104811A3 publication Critical patent/WO2003104811A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'expression différente du gène de la protéine régulatrice de réponse stéroïdogène aigüe (StAR) dans des régions spécifiques du cerveau de patients atteints de la maladie d'Alzheimer. Fondée sur cette découverte, l'invention concerne un procédé permettant de diagnostiquer ou de pronostiquer chez un sujet une maladie neurodégénérative, en particulier la maladie d'Alzheimer, ou de déterminer si un sujet présente un risque accru de développer une telle maladie. L'invention concerne de plus des méthodes de traitement et de prévention de la maladie d'Alzheimer et de troubles neurodégénératifs apparentés, au moyen du gène StAR et de produits géniques correspondants. Un procédé de criblage d'agents modulateurs de maladies neurodégénératives est également décrit.
PCT/EP2003/005910 2002-05-17 2003-06-05 Utilisation diagnostique et therapeutique de la proteine regulatrice de reponse steroidogene aigue pour traiter des maladies neurodegeneratives WO2003104811A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004511831A JP2005531305A (ja) 2002-06-10 2003-06-05 ステロイド産生急性調節タンパク質の神経変性疾患に関する診断的および治療的使用
AU2003240746A AU2003240746A1 (en) 2002-06-10 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
EP03730155A EP1512013A2 (fr) 2002-06-10 2003-06-05 Utilisation diagnostique et therapeutique de la proteine regulatrice de reponse steroidogene aigue pour traiter des maladies neurodegeneratives
US10/517,439 US20070118913A1 (en) 2002-05-17 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38672102P 2002-06-10 2002-06-10
EP02012815 2002-06-10
US60/386,721 2002-06-10
EP02012815.3 2002-06-10

Publications (2)

Publication Number Publication Date
WO2003104811A2 WO2003104811A2 (fr) 2003-12-18
WO2003104811A3 true WO2003104811A3 (fr) 2004-10-14

Family

ID=56290436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005910 WO2003104811A2 (fr) 2002-05-17 2003-06-05 Utilisation diagnostique et therapeutique de la proteine regulatrice de reponse steroidogene aigue pour traiter des maladies neurodegeneratives

Country Status (4)

Country Link
EP (1) EP1512013A2 (fr)
JP (1) JP2005531305A (fr)
AU (1) AU2003240746A1 (fr)
WO (1) WO2003104811A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005187A1 (fr) * 2022-07-01 2024-01-04 田辺三菱製薬株式会社 Composition et procédé d'évaluation de la réactivité de l'édaravone
KR20240035189A (ko) * 2022-09-08 2024-03-15 차의과학대학교 산학협력단 고령 여성의 난임 진단을 위한 바이오마커 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
WO1999052519A2 (fr) * 1998-04-14 1999-10-21 The General Hospital Corporation Methodes de traitement de troubles neuropsychiatriques
WO2000066728A1 (fr) * 1999-05-03 2000-11-09 Compugen Ltd. Homologues de star
WO2001032920A2 (fr) * 1999-11-03 2001-05-10 Metris Therapeutics Limited Agents impliques dans l'endometriose

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
WO1999052519A2 (fr) * 1998-04-14 1999-10-21 The General Hospital Corporation Methodes de traitement de troubles neuropsychiatriques
WO2000066728A1 (fr) * 1999-05-03 2000-11-09 Compugen Ltd. Homologues de star
WO2001032920A2 (fr) * 1999-11-03 2001-05-10 Metris Therapeutics Limited Agents impliques dans l'endometriose

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARON KATHLEEN M ET AL: "Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 21, 1997, 1997, pages 11540 - 11545, XP002241664, ISSN: 0027-8424 *
KALLEN C B ET AL: "UNVEILING THE MECHANISM OF ACTION AND REGULATION OF THE STEROIDOGENIC ACUTE REGULATORY PROTEIN", MOLECULAR AND CELLULAR ENDOCRINOLOGY, AMSTERDAM, NL, vol. 145, no. 1/2, 25 October 1998 (1998-10-25), pages 39 - 45, XP000900751, ISSN: 0303-7207 *
KIMOTO TETSUYA ET AL: "Neurosteroid synthesis by cytochrome P450-containing systems localized in the rat brain hippocampal neurons: N-methyl-D-aspartate and calcium-dependent synthesis.", ENDOCRINOLOGY, vol. 142, no. 8, August 2001 (2001-08-01), pages 3578 - 3589, XP002241665, ISSN: 0013-7227 *
STOCCO DOUGLAS M: "Tracking the role of a StAR in the sky of the new millennium.", MOLECULAR ENDOCRINOLOGY, vol. 15, no. 8, August 2001 (2001-08-01), pages 1245 - 1254, XP002241663, ISSN: 0888-8809 *

Also Published As

Publication number Publication date
WO2003104811A2 (fr) 2003-12-18
EP1512013A2 (fr) 2005-03-09
JP2005531305A (ja) 2005-10-20
AU2003240746A1 (en) 2003-12-22
AU2003240746A8 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
WO2005108999A3 (fr) Utilisation diagnostique et therapeutique de kcnj6 pour les maladies neurodegeneratives
WO2004026246A3 (fr) Procedes pour traiter les alterations de la memoire liees a l'age (aami), les deficits cognitifs legers (mci) et les demences au moyen d'inhibiteurs du cycle cellulaire
WO2006125830A3 (fr) Kcnn3 servant de cible diagnostique et therapeutique pour des maladies neurodegeneratives
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
DE69832688D1 (de) Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
WO2004070388A8 (fr) Utilisation diagnostique et therapeutique de la proteine scn2b pour des maladies neurodegeneratives
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
WO2004001422A3 (fr) Utilisation, en matiere de diagnostic et de therapie de maladies neurodegeneratives, de la proteine 2 (g3bp2) se fixant au domaine sh3 de la proteine activant la ras gtpase
WO2004003563A3 (fr) Utilisation diagnostique et therapeutique de la proteine et du gene ensadin-0581 dans le cadre des maladies neurodegeneratives
WO2002016636A3 (fr) Application diagnostique et therapeutique d'une proteine membranaire integrale associee aux caveolae a la maladie d'alzheimer et aux troubles neurodegeneratifs associes
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2004038411A3 (fr) Utilisations diagnostique et therapeutique d'un gene de l'ensadin-0289 et d'une proteine pour des maladies neurodegeneratives
WO2002046767A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees, parmi lesquelles diagnostic et traitement de la maladie d'alzheimer
WO2006134128A3 (fr) Methodes faisant appel a des proteines adarb2 cibles pour diagnostiquer et pour pronostiquer des maladies neurodegeneratives
WO2003104811A3 (fr) Utilisation diagnostique et therapeutique de la proteine regulatrice de reponse steroidogene aigue pour traiter des maladies neurodegeneratives
AU2579995A (en) Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
WO2005030947A3 (fr) Utilisation diagnostique et therapeutique d'une sulfotransferase pour des maladies neurodegeneratives
WO2003087403A3 (fr) Diagnostic et utilisation therapeutique d'une proteine golgi pour des maladies neurodegeneratives
WO2005085472A3 (fr) Utilisation diagnostique et therapeutique du gene et de la proteine mal2 pour les maladies neurodegenerescentes
WO2003100092A3 (fr) Utilisation diagnostique et therapeutique de cyp11a1 pour des maladies de neurodegenerescence
ATE464567T1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
WO2005059562A3 (fr) Diagnostic et utilisation therapeutique du gene humain hif3alpha et proteines associees contre les maladies neurodegeneratives
WO2004035823A3 (fr) Utilisation diagnostique et therapeutique des gene et proteine ensadin-0625 destinee a des maladies neurodegeneratives
AU2003208857A8 (en) Diagnostic and therapeutic use of caps
WO2003085131A3 (fr) Utilisation a des fins diagnostiques et therapeutiques de proteines et polynucleotides voutes pour des maladies neurodegeneratives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003730155

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004511831

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003730155

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007118913

Country of ref document: US

Ref document number: 10517439

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10517439

Country of ref document: US